CSE/BNXT (CSE/BNXT)

Canadian Securities Exchange: CSE/BNXT · CAD

CA$0.29

+0.00 (0.0%)· Recorded snapshot

Market cap	38.8M
Net income (ttm)	-9.1M
EPS (ttm)	-CA$0.07
Shares out	136.1M
Volume	31,000
Beta	1.42

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -9.1M
EPS (ttm): -CA$0.07
Market cap: 38.8M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CSE/BNXT indicators

Market & fundamental data

Available fields

148

Groups with data

Currency

CAD

Showing 148 of 148 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CAD
Country	Canada
Country code	CA
Earnings date	2026-11-27
Employees change	19
Employees growth	1,900%
Enterprise value	CAD 44.3M
Exchange	Canadian Securities Exchange
Financial currency	CAD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2017
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
ISIN number	CA0909741062
Last earnings date	2025-11-28
Last refreshed	2026-10-29
Market cap	CAD 38.8M
Next earnings date	2026-11-27
Price	CAD 0.29
Price currency	CAD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-29
Symbol	cse/BNXT
Website	https://www.bionxt.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-25.84%
FCF / EV yield	-10.29%
FCF yield	-11.74%
Industry forward P/E	34.89x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROA	-387.49%
ROA (5Y)	-280.52%
ROCE	130.6%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	CAD 11,827
EBIT	CAD -6.7M
EBITDA	CAD -6.7M
EPS	CAD -0.07
FCF per share	CAD -0.03
Financing cash flow	CAD 5.7M
Free cash flow	CAD -4.6M
Free cash flow minus SBC	CAD -7.5M
Income taxes	CAD -197,469
Investing cash flow	CAD 92,259
Net borrowing	CAD 1.3M
Net cash flow	CAD 1.2M
Net income	CAD -9.1M
Operating cash flow minus SBC	CAD -7.5M
Operating income	CAD -6.7M
Stock-based compensation	CAD 2.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	CAD -0.05
Interest coverage	-4.31
Long-term assets	CAD 258,350
Long-term liabilities	CAD 1.1M
Net cash (debt)	CAD -5.5M
Net cash / market cap	-14.14%
Piotroski F-Score	3
Property, plant and equipment	CAD 208,348
Shareholders' equity	CAD -6.3M
Tangible book value	CAD -6.3M
Tangible book value per share	CAD -0.05
Total assets	CAD 1.5M
Total cash	CAD 1.2M
Total debt	CAD 6.7M
Total liabilities	CAD 7.8M
WACC	13%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	CAD 1.3M
Current liabilities	CAD 6.7M
Current ratio	0.19
Net working capital	CAD -1M
Quick ratio	0.19
Working capital	CAD -5.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-8.39%
Shareholder yield	-8.39%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	CAD 0.42
1D price change	0%
1M price change	-14.93%
1M total return	-14.93%
1W price change	7.55%
1W total return	7.55%
1Y price change	-66.47%
1Y return CAGR	-66.5%
1Y total return	-66.47%
20-day SMA	CAD 0.31
200-day SMA	CAD 0.46
3M price change	-6.56%
3M total return	-6.56%
3Y price change	14%
3Y return CAGR	4.46%
3Y total return	14%
50-day SMA	CAD 0.33
50-day SMA vs 200-day SMA	50under200
52-week high	CAD 0.87
52-week high date	2025-10-29
52-week low	CAD 0.27
52-week low date	2026-10-21
5Y price change	-75.43%
5Y return CAGR	-24.48%
5Y total return	-75.43%
6M price change	-38.71%
6M total return	-38.71%
All-time high	CAD 3.55
All-time high date	2020-04-22
All-time low	CAD 0.17
All-time low date	2024-06-21
Average true range (ATR)	CAD 0.02
Average volume	30.1K
Beta (1Y)	-0.81
Beta (2Y)	0.06
Beta (5Y)	1.42
Change from 52-week high	-67.24%
Change from 52-week low	7.55%
Change from all-time high	-91.97%
Change from all-time low	67.65%
Change from open	0%
Day's gap	0%
Dollar volume	CAD 8,835
High price	CAD 0.29
Low price	CAD 0.29
Monthly RSI	38.79
Open price	CAD 0.29
Previous close	CAD 0.29
Price vs 150-day SMA	-32.11%
Price vs 20-day SMA	-8.51%
Price vs 200-day SMA	-38.54%
Price vs 50-day SMA	-13.27%
Relative volume	1.03
RSI	41.92
Sharpe ratio	-0.5
Sharpe ratio (3Y)	0.26
Sharpe ratio (5Y)	0.03
Sortino ratio	-0.66
Sortino ratio (3Y)	0.47
Sortino ratio (5Y)	0.11
Volume	31K
Weekly RSI	31.34
YTD price change	-55.47%
YTD total return	-55.47%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	128.8M
Shares change (QoQ)	3.76%
Shares change (YoY)	8.39%
Shares held by insiders	5.33%
Shares outstanding	136.1M

Deeper analysis on CSE/BNXT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CSE/BNXT report

Is a complete CSE/BNXT research report available?

No complete published report is available for cse/BNXT (CSE/BNXT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

CSE/BNXT (CSE/BNXT)

Price

Financial snapshot

Fair-value bridge

Latest news · CSE/BNXT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CSE/BNXT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CSE/BNXT

Frequently asked questions